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chemotherapy to evaluate the rate of second cancers and their sites 
according to the extension of radiation fields. 
Materials and Methods: From 1990 to 1995, 140 patients (pts) with 
early-stage HL (IA, IB, IIA ± bulky) received 4 cycles of ABVD and then 
they were randomized to receive STNI (36 Gy to involved sites and 30 
Gy to uninvolved sites) or IF (36 Gy to involved sites). The endpoints 
of this review were to assess the rate of late toxicity in term of SPC 
and the spatial relationship between radiation fields extent and SPC. 
We used the topographical criteria defined by Dorr1 to localize SPC 
compared to RT fields. Event-free survival (EFS) and overall survival 
(OS) were estimated by Kaplan-Meier method. Crude and age-adjusted 
incidence rates of SPC were calculated by Poisson regression.  
Results: After a median follow-up of 203 months, 24 SPC were 
observed: 7 cutaneous basal cell carcinomas, 1 MDS, 16 solid tumours 
(11 breast, 2 prostate, 1 ovary, 1 skin, 1 colon). For this study we 
evaluated only solid cancers.  13 SPC were in STNI arm, 3 in IFRT (p 
0.014). Median time to second malignancies was 172 months in STNI 
and 178 in IFRT. IR (incidence rate/1000 person-years) 12.9 in STNI 
and 2.76 in IFRT (p 0.014). In a univariate analysis, the second 
malignancies risk is higher in STNI versus IFRT (hazard ratio 4.40, 95% 
CI). According to the topographic criteria, SPC were located as listed 
below: 
 
 In-field Margin Adjacent Distant
Breast 8 3 0 0 
Other 0 0 2 3 
 
Dose at in-field region was 36 Gy in all cases. 
Median age at breast cancer diagnosis was 43years (27y at HL 
diagnosis); median age at diagnosis of other cancers was 62y (49y at 
HL diagnosis). 7 breast cancers (5 infiltrating carcinoma and 2 in situ) 
were treated with conservative surgery and in 5 cases radiation-
therapy was performed. 2 breast cancer pts died (1 myocardial 
infarction, 1 disease progression). All the remaining pts are alive and 
with no evidence of both tumours. 
Conclusions: Combined modality treatment is currently the treatment 
of choice for early-stage HL. In this setting of patients, RT contributes 
to achieving a high cure-rate. Despite the fact that the optimal size of 
RT fields and dose are still unknown, our data confirm that reducing 
of field size to IF is safe both in terms of cure rate and reduction of 
second cancers. 
1) Dörr W, Herrmann T Second primary tumors after radiotherapy for 
malignancies. Treatment related parameters. Strahlenther Onkol 
2002; 178: 357-62 
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Purpose/Objective: Glioblastoma multiforme (GBM) is the most 
aggressive type of brain cancer in adults. It is suggested that tumour 
microenvironment might influence treatment outcome of cancer 
patients. The aim of this study was to evaluate the impact of 
inflammation on treatment response and survival of GBM patients. 
Materials and Methods: Between Jan 2006 and Dec 2008, 42 patients 
were operated and received postoperative radiotherapy 
(±chemotherapy). Surgically excised GBM tissues were immuno-
histochemically examined for CD63 expression. Since CD63 is 
expressed on inflammatory cells (monocytes, macrophages, 
granulocytes), the number of CD63-positive (CD63+) cells per 
microscopic field was determined. Also, haematoxylin-eosin stained 
tumour sections were histologically examined for overall proportion of 
necrosis (%) and microvascular proliferations (MP; low, medium, high). 
Finally, CD63 expression was correlated with patients overall survival. 
Results: Immunohistochemical parameters were examined by 2 
independent researchers whose results were in good accordance 
(R=0.8, p<0.0001). The number of CD63+ inflammatory cells per 
microscopic field was 62.1±23.1 (mean±SD). A significant association 
was found between the number of CD63+ cells and the proportion of 
necrosis (p=0.004). Also, a correlation between the number of CD63+ 
cells and the proportion of MP was detected (p=0.009). Median 
survival time of the study group was 10.0 months (95% CI 9.0-11.0). 
However, the survival time clearly depended on the number of CD63+ 
cells in GBM tissue (log rank test, p=0.003). Median survival times for 
patients with low (less than median) and high (equal or more than 
median) number of CD63+ cells were 9.0 months (95% CI 8.1-9.9) and 
12.0 months (95% CI 8.5-15.5) respectively. In multivariate analysis, 
the number of CD63+ cells emerged as a significant independent 
predictor for longer overall survival (HR 2.4, 95% CI 1.2-5.1, p=0.02). 
Conclusions: Present study revealed a beneficial role of inflammation 
on survival of GBM patients. In patients with higher number of CD63+ 
cells prior radiotherapy, significantly longer survival times were 
achieved. Additionally, inflammatory reaction was associated with 
tumour micromilieu: there were more inflammatory cells in the 
presence of high proportion of necrosis and MP. Clearly, more studies 
are needed to evaluate the role of inflammation and tumour 
microenvironment on GBM treatment outcome. 
This work was supported by Institutional Research Funding 
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Purpose/Objective: Re-irradiation has been shown to be an option for 
recurrent high-grade glioma patients with proven but limited efficacy. 
Furthermore, bevacizumab exerts certain efficacy in combination with 
chemotherapy or as monotherapy and was safely tested in 
combination with radiotherapy for re-treatment in smaller studies. 
This report gives an update on the outcome of patients treated at the 
University hospital of Munich. To our knowledge, this is the largest 
cohort including patients treated with both re-irradiation and 
bevacizumab to date. 
Materials and Methods: After receiving standard radiotherapy (with or 
without TMZ) patients with recurrent malignant glioma were treated 
with bevacizumab (10mg/kg intravenously at d1 and d15) during re-
irradiation. Median prescribed radiation dose during re-treatment was 
36Gy, conventionally fractionated. 
Results: 71 patients re-irradiated in a single institution were 
retrospectively analyzed. Patients either received bevacizumab 
(N=57), other substances (N=4) or radiation alone (N=10). Re-
irradiation was tolerated well regardless of the additional therapy. In 
one patient with bevacizumab a wound dehiscence occurred, one 
patient suffered from deep vein thrombosis resulting in pulmonary 
embolism. One patient died of a perforated sigma diverticulitis. Post-
recurrence survival was significantly increased in patients receiving 
bevacizumab (p=0.003, log-rank test) as well as progression-free 
survival (p=0.005, log-rank test). KPS, surgery, MGMT, sex, WHO grade 
and age showed no statistically significant improvement in neither PFS 
nor survival. 
Conclusions: Re-irradiation with bevacizumab remains a feasible and 
highly effective treatment schedule. Studies on further salvage 
strategies and timing of sequential treatment options vs. observation 
are warranted.  
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Purpose/Objective: In order to define new prognostic subgroups in 
patients with glioblastoma (GBM) a method is presented how to derive 
potentially prognostic miRNA patterns employing a large screen (> 
1,200 miRNAs) from paraffin tissues including associated 
methodological problems and pitfalls. 
Materials and Methods: Thirty-six GBM patients treated in a single 
institution basically according to the EORTC/NCIC protocol between 
1/2009 - 12/2010 were included in this retrospective analysis. For 
microarray analysis, the febit biochip 'Geniom® Biochip MPEA homo 
sapiens' was used. Total RNA was isolated from FFPE slides, altogether 
over 1,200 different miRNAs were analyzed. In order to define 
significant patterns, a Cox regression analysis for each single miRNA 
was performed using long-term survival (split at 450 days) as censor; 
significant miRNAs (without multiple-testing correction) were chosen 
and a hierarchical clustering analysis was performed; survival of the 
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respective patient subgroups were compared by log-rank testing as 
was done for other patient-related factors. Subsequently, a miR-walk 
database search was done to determine potential targets of the 
dysregulated miRNAs. 
Results: It was possible to segregate a distinct miRNA expression 
pattern (consisting of 29 miRNAs) in patients with GBM; this was 
different to a previously published one consisting of 30 miRNAs 
whereas both results are not directly comparable due to 
methodological differences. Both subgroups defined by the pattern 
had a significantly altered median overall survival from 226 to 544 
days (log-rank-test, p = 0.005). Pattern and prediction were 
independent of MGMT methylation status. Further prognostic factors 
could not be identified; even MGMT methylation status did not reach 
statistic significance in this dataset. 
Conclusions: This study introduces a new methodology that can be 
used for generating miRNA patterns which in turn could have 
prognostic impact in GBM patients. Array technology is a critical 
factor so that prospective trials with larger case numbers and a 
clearly defined work-flow/array design/background correction are 
needed to 1) generate further hypotheses, 2) make results between 
study groups comparable and 3) to validate these results.  
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Purpose/Objective: Although radiotherapy is generally effective in 
patients with painful bone metastases, up to 40% of patients do not 
obtain sufficient pain relief. Furthermore, 50% of patients eventually 
experience progressive pain. Hence, theoretically, a large patient 
group should be given reirradiation, especially since survival of cancer 
patients increases. Little is known about clinical patterns for 
reirradiation of painful bone metastases and its effectiveness in terms 
of pain palliation. In this historical cohort study we evaluated 
reirradiation of painful bone metastases and its effectiveness in 
clinical practice.  
Materials and Methods: Between January 2000 and July 2011, 282 
patients were reirradiated for painful bone metastases at our center. 
Reirradiation was defined as retreatment of a painful bone metastasis 
≥ 4 weeks after initial irradiation for pain. Response to treatment was 
defined as a decrease in pain at the reirradiated site, as reported by 
the patient at the physician’s interview in person or by telephone, 
between 2 to 12 weeks after retreatment. Median moment of 
response assessment was 4 weeks after reirradiation (range 2-12). 
Patient and treatment characteristics were retrospectively collected 
from patient records. McNemar’s test for dependent data was used to 
compare proportions. Overall pain response rate was calculated for 
patients with available follow-up.  
Results: At the time of writing, the data of 187 patients were 
available. Of those, 54% were male, mean age was 64.1±12.3 years. 
Primary tumors were prostate in 31% of patients, breast in 27%, lung 
in 14% and other primaries in 28% of patients. The reirradiated 
metastases were localized in the spine in 48% of patients, pelvis in 
34%, long bones in 5% and other locations in 13% of patients. At 
reirradiation, patients had a lower functional status, had more pain 
and used more pain medication compared to initial radiotherapy 
(table 1). Reasons for reirradiation were mostly progression after 
initial response in 77% of patients and less often insufficient response 
or no response (12% vs.11% of patients, respectively). Median time-to-
reirradiation was 7 months (range 1-164). Reirradiation schedules 
differed significantly for initial and reirradiation, with more non 
standard schedules used for reirradiation (table 1). Follow-up data on 
response were available in 128 of 187 patients (68%). The overall 
response rate was 66% (95% CI, 0.58-0.74). 
 
 
Conclusions: Response to reirradiation occurred in 66% of patients, 
although it must be noted that in clinical follow-up was relatively poor 
in this study. Updated results will be presented in April 2013. 
   
PD-0531   
Spinal instability, as defined by the spinal instability neoplastic 
score, is associated with radiotherapy failure 
J.M. van der Velden1, M. Huisman2, M. van Vulpen1, M.A.A.J. van den 
Bosch2, H.M. Verkooijen2, J.J. Verlaan3 
1University Medical Center Utrecht, Imaging Division Department of 
Radiation Oncology, Utrecht, The Netherlands  
2University Medical Center Utrecht, Imaging Division Department of 
Radiology, Utrecht, The Netherlands  
3University Medical Center Utrecht, Department Orthopaedic Surgery, 
Utrecht, The Netherlands  
 
Purpose/Objective: Recently, the Spinal Instability Neoplastic Score 
(SINS) was proposed to objectively determine spinal instability in 
patients with spinal metastases based on clinical and radiological 
examinations. The SINS score, ranging from 0 to 18 points, divides 
patients into three categories; stable (0-6), potentially unstable (7-12) 
and unstable (13-18). Early recognition of (impending) spinal 
instability may prevent painful collapse and neurologic deficits by 
timely referral for surgical stabilization. Presently, it is not known 
whether spinal instability negatively influences radiotherapy 
outcomes. The purpose of this study was to determine the effect of 
spinal instability, as defined by the SINS score, on radiotherapy 
failure.  
Materials and Methods: We performed a retrospective matched case-
control study in a radiotherapy-based patient population. Cases were 
defined as patients who underwent retreatment (reirradiation, 
surgical stabilization or conservative treatment) for symptomatic 
metastases of the thoracic or lumbar spine after radiation therapy. 
Controls did not undergo retreatment after radiation therapy and 
were matched for follow-up at a 2:1 ratio. Cases (N=41) and controls 
(N=82) were selected from all patients treated between January 2009 
and December 2010 at our center (N=712). Exclusion criteria applied 
were prior treatment or orthopedic consultation for the painful lesion, 
an aberrant radiotherapy regimen, intramedullar lesions and the use 
of multiple fields at initial radiotherapy. Age, sex, functional status 
(WHO< 1 or >2), primary tumor, localization, number of bone 
metastases, symptoms, radiotherapy schedule (1 x 8 or 5 x 4 Gy) and 
use of systemic therapy were retrieved from patients records. A spinal 
surgeon, blinded for the outcome, scored instability using the SINS 
criteria on the CT-scans of both cases and controls. Patient records 
were independently reviewed by two observers to determine the SINS 
component pain; discrepancies were reviewed by a radiation 
oncologist and consensus was obtained. Univariate and multivariate 
conditional logistic regression models were used for case-control 
comparison.  
Results: Retreatment consisted of reirradiation in 80%, surgery 10% 
and conservative management (intrathecal pump implant or plaster 
jacket) in 10%. The median SINS score was 9 (range 4-16) for cases and 
7 (range 1-16) for controls. After multivariate adjustment (Table 1), 
the total SINS score and the categorized SINS, were significantly and 
independently associated with radiotherapy failure (adjusted odds 
ratio for total SINS, 1.2; 95% CI, 1.1-1.5). 
 
